HC Wainwright Raises Theravance Biopharma (NASDAQ:TBPH) Price Target to $27.00

Theravance Biopharma (NASDAQ:TBPH) had its price objective boosted by stock analysts at HC Wainwright from $20.00 to $27.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 93.41% from the stock’s previous close.

Several other research analysts also recently issued reports on TBPH. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $40.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 3rd. Oppenheimer started coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective for the company. Finally, Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Buy” and a consensus price target of $25.40.

Theravance Biopharma Trading Down 26.3%

TBPH stock opened at $13.96 on Monday. The company has a market capitalization of $707.35 million, a P/E ratio of 24.49 and a beta of 0.17. The business has a 50 day simple moving average of $19.26 and a 200-day simple moving average of $16.88. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $21.03.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently made changes to their positions in TBPH. Caitong International Asset Management Co. Ltd boosted its holdings in Theravance Biopharma by 51.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,408 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Theravance Biopharma during the 4th quarter valued at approximately $6,342,000. Invesco Ltd. boosted its stake in shares of Theravance Biopharma by 622.2% during the 4th quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company’s stock worth $3,329,000 after acquiring an additional 153,306 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Theravance Biopharma in the 4th quarter worth approximately $705,000. Finally, Susquehanna Portfolio Strategies LLC grew its holdings in shares of Theravance Biopharma by 208.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 29,313 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company reports a strong cash position (about $326.5M at Q4 2025 and ~ $400M expected at end-Q1 2026 including milestones), no debt, and confidence in a $100M 2026 TRELEGY milestone — provides near-term runway. PR Newswire Release
• Positive Sentiment: Board announced accelerated strategic review and a restructuring expected to cut the cost base by ~60% (~$70M), targeting $60–70M of annualized cash flow; company is narrowing to a portfolio focused on YUPELRI, which generated durable revenues (FY2025 net sales recognized by Viatris $266.6M, +12% YoY). PR Newswire Release
• Neutral Sentiment: Analyst actions are mixed but still show some institutional support: BTIG cut its price target to $21 but kept a Buy rating, while HC Wainwright recently raised its target to $27 — signals divergent views on post-trial valuation. BTIG / StreetInsider HC Wainwright note
• Negative Sentiment: Topline from the Phase 3 CYPRESS study: ampreloxetine did not meet the primary endpoint (OHSA composite score) in patients with neurogenic orthostatic hypotension due to MSA — the clinical failure removes the lead late‑stage opportunity. Benzinga: Trial Miss
• Negative Sentiment: Management said it is accelerating a strategic review that could include a sale; media report the company is working with advisors (Lazard) — this signals material uncertainty about TBPH’s standalone future and likely near-term volatility. Reuters: Strategic Review
• Negative Sentiment: Market response: shares plunged and trading was briefly halted; unusually large put-option activity suggests elevated short-term bearish positioning and higher volatility. Proactive Investors: Market Reaction

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.